Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Photo of John Evans
Individual Investor

John Evans

Overview

Edit Overview Section
Number of Portfolio Companies 2
Number of Exits 
Unlock for free
  • Investor Type 
    obfuscation
  • Investor Stage 
    obfuscation
  • Number of Exits 
    obfuscation
John Evans is the CEO of Beam Therapeutics. He attended The Wharton School.

Personal Investments

Edit Personal Investments Section
Number of Investments 2
John Evans has made 2 investments. Their latest investment was Seed Round - Terrain Bio on
obfuscation
, when Terrain Bio raised
obfuscation
.
Announced Date  
Organization Name  
Lead Investor  
Funding Round  
Money Raised  
obfuscation
Terrain Bio Logo
Terrain Bio
—
Seed Round - Terrain Bio Logo
Seed Round - Terrain Bio
obfuscation
obfuscation
Kicksend Logo
Kicksend
—
Seed Round - Kicksend Logo
Seed Round - Kicksend
obfuscation

Exits

Edit Exits Section
Number of Exits 
Unlock for free
John Evans has
obfuscation
exit - Terrain Bio. John Evans has
obfuscation
exits. Their most notable exits are Terrain Bio and  Kicksend.
  • Terrain Bio Logo
    Terrain Bio Terrain BioSciences accelerates RNA-based therapeutics and vaccine development using AI and proprietary platforms.
  • Kicksend Logo
    Kicksend Kicksend is an easy-to-use application to send, receive and print photo albums.

Jobs

Edit Jobs Section
Number of Current Jobs 3
Number of Past Jobs 5
John Evans has 3 current jobs including Venture Partner at ARCH Venture Partners, CEO at Beam Therapeutics, and CEO at DecisionCFO. Additionally, John Evans has had 5 past jobs including VP Business Development & Operations at Agios Pharmaceuticals.
Organization Name  
Title At Company  
Start Date  
End Date  
Agios Pharmaceuticals Logo
Agios Pharmaceuticals
VP Business Development & OperationsSep 2009Apr 2017
Infinity Pharmaceuticals Logo
Infinity Pharmaceuticals
Director, Product DevelopmentJul 2006Sep 2009
McKinsey & Company Logo
McKinsey & Company
Senior AssociateJun 2005Jul 2006
MedImmune Logo
MedImmune
Summer Associate, Corporate DevelopmentJun 2004Aug 2004
McKinsey & Company Logo
McKinsey & Company
Business AnalystJun 2001Jun 2003

Board and Advisor Roles

Edit Board and Advisor Roles Section
Number of Current Board & Advisor Roles 3
John Evans holds 3 board and advisor roles including Board Member at Beam Therapeutics, Board Member at Prime Medicine, and Advisor at Factr.

Related Hubs

Edit Related Hubs Section
Hub Name  
CB Rank (Hub)  
Medical Public Companies With More Than 500 Employees Logo
Medical Public Companies With More Than 500 Employees
10,899
Medical Public Companies With More Than 50 Employees Logo
Medical Public Companies With More Than 50 Employees
10,419
Medical Public Companies With Fewer Than 1000 Employees Logo
Medical Public Companies With Fewer Than 1000 Employees
19,984
East Coast Biotechnology Public Companies Logo
East Coast Biotechnology Public Companies
11,470
Omega Funds Portfolio Companies Logo
Omega Funds Portfolio Companies
85,291
Redmile Group Portfolio Companies Logo
Redmile Group Portfolio Companies
78,859
Northeastern US Medical Companies (Top 10K) Logo
Northeastern US Medical Companies (Top 10K)
5,549
Therapeutics Public Companies With Fewer Than 1000 Employees Logo
Therapeutics Public Companies With Fewer Than 1000 Employees
11,935
Perceptive Advisors Portfolio Companies Logo
Perceptive Advisors Portfolio Companies
66,727
Eight Roads Ventures Portfolio Companies Logo
Eight Roads Ventures Portfolio Companies
41,765

Education

Edit Education Section
John Evans studied at University of Pennsylvania, Yale University, and  Wharton School of the University of Pennsylvania.

Recent News and Activity

Edit Recent News and Activity Section
Number of News Articles 19
Funding Round•Feb 12, 2025
Terrain Bio raised
obfuscation
from Brainstorm Ventures and 10 other investors
Discover more funding rounds
News•Dec 4, 2020
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Nov 2, 2020
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 21, 2020
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Mar 31, 2020
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Feb 29, 2020
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Feb 12, 2020
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Dec 20, 2019
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Dec 1, 2019
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Nov 18, 2019
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
View All
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(9fd75b2 1)
|